Hyperglycaemia and cardiovascular disease

被引:51
作者
Bartnik, M.
Norhammar, A.
Ryden, L.
机构
关键词
coronary artery disease; diabetes; impaired glucose tolerance; prognosis;
D O I
10.1111/j.1365-2796.2007.01831.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bartnik M, Norhammar A, Ryden L (Karnsjukhuset Skovde; and Karolinska Institutet; Stockholm, Sweden). Hyperglycaemia and cardiovascular disease (Review). J Intern Med 2007; 262: 145-156. Coronary artery disease and type 2 diabetes are chronic diseases of substantial and growing prevalence. Their coincidence is common, markedly enhancing mortality and morbidity. The risk for cardiovascular disease increases along a spectrum of blood glucose concentrations already apparent at levels regarded as normal. Accordingly, strategies for the early detection of glucometabolic disturbances are needed to find ways to prevent the occurrence of cardiovascular complications or to treat them already at an early stage. More specifically, abnormal glucose tolerance is almost twice as common amongst patients with a myocardial infarction as in population-based controls and a normal glucose regulation is indeed less common than abnormal glucose metabolism also amongst patients with stable coronary artery disease. Already an abnormal glucose tolerance is a strong risk factor for future cardiovascular events after an acute myocardial infarction. An oral glucose tolerance test should, therefore, be a part of the evaluation of total risk in all patients with coronary artery disease. As glucose disturbances are common and easy to detect, they may be suitable targets for novel secondary preventive efforts.
引用
收藏
页码:145 / 156
页数:12
相关论文
共 94 条
[31]   Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans - Role of oxidative stress [J].
Esposito, K ;
Nappo, F ;
Marfella, R ;
Giugliano, G ;
Giugliano, F ;
Ciotola, M ;
Quagliaro, L ;
Ceriello, A ;
Giugliano, D .
CIRCULATION, 2002, 106 (16) :2067-2072
[32]  
FOX CS, 1999, JAMA-J AM MED ASSOC, V281, P1291
[33]  
FULLER JH, 1980, LANCET, V1, P1373
[34]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[35]   Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial [J].
Gerstein, H. C. ;
Yusuf, S. ;
Holman, R. R. ;
Bosch, J. ;
Anand, S. ;
Avezum, A. ;
Budaj, A. ;
Chiasson, J. ;
Conget, I. ;
Dagenais, G. ;
Davis, M. ;
Diaz, R. ;
Dinccag, N. ;
Enjalbert, M. ;
Escalante, A. ;
Fodor, G. ;
Hanefeld, M. ;
Hedner, T. ;
Jolly, K. ;
Keltai, M. ;
Laakso, M. ;
Lanas, F. ;
Lonn, E. ;
McQueen, M. ;
Mohan, V. ;
Phillips, A. ;
Piegas, L. ;
Pirags, V. ;
Probstfield, J. ;
Shaw, J. ;
Schmid, I. ;
Teo, K. ;
Zimmet, P. ;
Zinman, B. ;
Gerstein, H. C. ;
Yusuf, S. ;
Bosch, J. ;
Pogue, J. ;
Sheridan, P. ;
Dinccag, N. ;
Hanefeld, M. ;
Hoogwerf, B. ;
Laakso, M. ;
Mohan, V. ;
Shaw, J. ;
Zinman, B. ;
Holman, R. R. ;
Diaz, R. ;
Ahuad Guerrero, R. ;
Albisu, J. .
LANCET, 2006, 368 (9541) :1096-1105
[36]  
GOLDBERGER E, 1945, NEW YORK STATE J MED, V45, P391
[37]   Diabetes and decline in heart disease mortality in US adults [J].
Gu, K ;
Cowie, CC ;
Harris, MI .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (14) :1291-1297
[38]   CARDIOVASCULAR RISK-FACTORS IN CONFIRMED PREDIABETIC INDIVIDUALS - DOES THE CLOCK FOR CORONARY HEART-DISEASE START TICKING BEFORE THE ONSET OF CLINICAL DIABETES [J].
HAFFNER, SM ;
STERN, MP ;
HAZUDA, HP ;
MITCHELL, BD ;
PATTERSON, JK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (21) :2893-2898
[39]   Risk factors for myocardial infarction and death in newly detected NIDDM: The diabetes intervention study, 11-year follow-up [J].
Hanefeld, M ;
Fischer, S ;
Julius, U ;
Schulze, J ;
Schwanebeck, U ;
Schmechel, H ;
Ziegelasch, HJ ;
Lindner, J .
DIABETOLOGIA, 1996, 39 (12) :1577-1583
[40]  
HARRIS M, 1979, DIABETES, V28, P1039